Sangui BioTech International Inc. Stock Analysis SGBI
Sangui BioTech International, Inc. is a holding company, which engages in the research, development, manufacture, and sale of medical and cosmetic products. The company is headquartered in Hamburg, Hamburg. The firm develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). The company is engaged in seeking to market and selling its products through partnerships with industry partners across the world. The company focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. The company focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. The company offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
Read More Sangui BioTech International Inc (SGBI) Chart
Key Statistics of Sangui BioTech International Inc (SGBI)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
90.00P/E Ratio (TTM)
-52 Week Range
Market Cap
40.00KAvg. Volume
2886.25Dividend Yield
-Financial Metrics & Statements of Sangui BioTech International Inc (SGBI)
FAQ's for Sangui BioTech International Inc (SGBI)
- According to Musaffa’s Shariah screening methodology, Sangui BioTech International Inc (SGBI) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.